Aimmune Therapeutics Inc (AIMT)

NASDAQ
34.49
0.00(0.00%)
  • Volume:
    0
  • Day's Range:
    34.48 - 34.56
  • 52 wk Range:
    34.48 - 34.56
Trading near 52-week High

Aimmune Therapeutics Inc has hit the highest price it has traded for over the last year (52 week period). This is a technical indicator that can be used to analyze the stock's current value and predict future price movement.

1 / 2

AIMT Overview

Prev. Close
34.49
Day's Range
34.48-34.56
Revenue
-
Open
34.56
52 wk Range
34.48-34.56
EPS
-4.49
Volume
0
Market Cap
2.27B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
674,519
P/E Ratio
-
Beta
2.09
1-Year Change
0%
Shares Outstanding
65,766,796
Next Earnings Date
-
What is your sentiment on Aimmune Therapeutics Inc?
or
Market is currently closed. Voting is open during market hours.

Aimmune Therapeutics Inc News

Aimmune Therapeutics Inc Analysis

Aimmune Therapeutics Inc Company Profile

Aimmune Therapeutics Inc Company Profile

Employees
339

Aimmune Therapeutics, Inc., a biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is PALFORZIA used for the treatment of patients with peanut allergy. The company also engages in the research and development of AR201, a CODIT product candidate, which is in Phase II clinical trial for the treatment of egg allergy in pediatric and young adult patients; and other CODIT product candidates targeting food allergies, such as cow’s milk allergy. Aimmune Therapeutics, Inc. has a strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics; and clinical collaboration agreement with Regeneron Ireland Unlimited Company and Sanofi Biotechnology SAS to study PALFORZIA with adjunctive dupilumab in peanut-allergic patients. The company was formerly known as Allergen Research Corporation and changed its name to Aimmune Therapeutics, Inc. in May 2015. Aimmune Therapeutics, Inc. was founded in 2011 and is headquartered in Brisbane, California. Aimmune Therapeutics, Inc. is a subsidiary of Société des Produits Nestlé S.A.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving Averages
Technical Indicators
Summary
  • why it stopped the transaction anybody knows please ?
    0
    • Nestlé bought all the available stock in the market.
      0
  • short this stock, whats up?
    1
    • the rocket it s close, hold on boooooooys
      0
      • What is happening?
        0
        • this will explode hardly.
          0
          • they were waiting for me to buy in....now it launches
            0
            • did this stock froze .whats going on
              0
              • Yeah I’m confused too
                0
            • Yes this is great news....but NEVER hold for some made up price like $75. There is always chop in the market and its always, always, always a good idea to take profits. Good Luck
              1
              • Ahahaha, thats what I am talking about I am rich, dont sell guys before $75
                0
                • sell or hold here?
                  0
                  • Hold it , are you kidding me ?
                    0
                  • Nasdaq Diggernew to the game never had a company sell on me
                    0